Reading Room

Featured Reading

“Conflicts-of-Interest Policies for Academic Medical Centers: Recommendations for Best Practices”.

The Pew Charitable Trusts, in partnership with an expert task force of leaders from academic medicine and other partners, released a set of 15 best practices for medical schools and teaching hospitals to use in developing conflict-of-interest policies. These experts have set a high standard for schools and teaching hospitals, with recommendations that COI policies should include banning pharmaceutical representatives from any interaction with students to ensuring that affiliate hospitals and clinics are following the same policies. Read more.

Selected Articles

Ornstein, Charles, et al. “Now There’s Proof: Docs Who Get Company Cash Tend to Prescribe More Brand-Name Meds.” ProPublica, March 17, 2016

Molchan, Susan. “Responding to parts 2-3 of New England Journal of Medicine’s series on pharma-MD relations” and “Criticism of NEJM’s defense of industry-physician relations.”, May 21 and May 14, 2015

Poses, Ray. “Say It Ain’t So: Logical Fallacies in Defense of Conflicts of Interest … in the New England Journal of Medicine?.” Health Care Renewal, May 21, 2015

Whoriskey, Peter – The Washington Post Special Report “Can Medical Research Be Trusted?”

  • “Rising painkiller addiction shows damage from drugmakers’ role in shaping medical opinion” December 30, 2012
  • “Antidepressants to treat grief? Psychiatry panelists with ties to drug industry says yes” December 26, 2012
  • “As drug industry’s influence over research grows, so does the potential for bias” November 24, 2012
  • “Medicare overspending on anemia drug” August 9, 2012
  • “Anemia drugs made billions, but at what cost?” July 19, 2012
  • “The rise and fall of a billion-dollar drug” July 19, 2012

Friedman, Richard A. “A Call for Caution on Antipsychotic Drugs.” The New York Times, September 24, 2012

Kesselheim, Aaron S. et. al. “Conflict of Interest Reporting by Authors Involved in Promotion of Off-Label Drug Use: An Analysis of Journal Disclosures.” PLOS Medicine, August 7, 2012

Chressanthis, George A. et. al. ” Can Access Limits on Sales Representatives to Physicians Affect Clinical Prescription Decisions? A Study of Recent Events With Diabetes and Lipid Drugs.” Journal of Clinical Hypertension, July 2012

Pham-Kanter, Genevieve et. al. “Effect of Physician Payment Disclosure Laws on Prescribing.” JAMA Internal Medicine, May 2012

Steinman, Michael et. al. “Industry Support of CME — Are We at the Tipping Point?” JAMA Internal Medicine, March 2012

Wolston, Maran. “An MS Patient Loses Trust When She Finds Out Her Doctor is Paid by Drug Companies.” Health Affairs, 30. No.12: 2449-2452, 2011

Spurling, Geoffrey K. et. al. “Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians’ Prescribing: A Systematic Review,” PLoS Medicine, October 19, 2010

Ross, Joseph S. and Harlan M. Krumholz. “Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications,” Mayo Clinic Proceedings, February 2010

Shrank, William. “Change We Can Believe In: Requiring Better Evidence for Formulary Coverage” AJMC, September 2009

Chimonas, Susan and Jerome Kassirer. “No More Free Drug Samples?” PLOS Medicine, May 2009

Coleman, David. “Establishing Policies for the Relationship Between Industry and Clinicians: Lessons Learned From Two Academic Health Centers.” Academic Medicine, 83: 882-887, 2008

Campbell E.G., R.L. Gruen, J. Mountford, L.G. Miller, P.D. Cleary, and D. Blumenthal. “A National Survey of Physician-Industry Relationships.” New England Journal of Medicine, 356: 1742-1750, 2007

Chimonas, Susan, Troyen A. Brennan, and David J. Rothman. “Physicians and Drug Representatives: Exploring the Dynamics of the Relationship.” Society for General Internal Medicine, 22:184-190, 2007

Fugh-Bernman, Adriane and Shahram Ahari. “Following the Script: How Drug Reps Make Friends and Influence Doctors.” PLoS Medicine, 4(4): 0621-0625, 2007

Oldani, Michael. “Can Doctors Take Back the Script?  Understanding the Total System of Prescription Generation.”  Atrium: The Report of the Northwestern Medical Humanities and Bioethics Program,  Summer, Issue 4: 15-17, 28, 2007

Zipkin DA, and M.A. Steinman. “Interactions Between Pharmaceutical Representatives and Doctors in Training. A Thematic Review.” J Gen Intern Med,  20(8):7, 2005

Mitzik, Natalie and Robert Jacobson. “Are Physicians ‘Easy Marks’? Quantifying the Effects of Detailing and Sampling on New Prescriptions.” Management Science, 50(12): 1704-1715, 2004

Oldani, Michael. “Thick Prescription: Toward an Interpretation of Pharmaceutical Sales Practices.” Medical Anthropology Quarterly, 18(3): 325-356, 2004

Dana, Jason and George Loewenstein. “A Social Science Perspective on Gifts to Physicians from Industry.” JAMA 290(2): 252-255, 2003

Katz, Dana, Arthur L. Caplan and Jon F. Merz. “All Gifts Large and Small.”  American Journal of Bioethics, 3(3): 39-46, 2003

Wazana, Ashley. “Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?” JAMA. 283(3): 373-380, 2000

Chew, Lisa D., Theresa S. O’Young, Thomas K. Hazlet, Katherine A. Bradley, Charles Maynard, and Daniel S. Lessler. “A Physician Survey of the Effect of Drug Sample Availability on Physicians’ Behavior.” J Gen Intern Med, 15(7): 478-483, 2000

Lexchin J. “Interactions Between Physicians and the Pharmaceutical Industry: What Does the Literature Say?” CMAJ, 149(10):1401-7, 1993

McKinney W.P., D. Schiedermayer, N. Lurie, D. Simpson, J. Goodman, and E. Rich. “Attitudes of Internal Medicine Faculty and Residents Toward Professional Interaction with Pharmaceutical Sales Representatives.” JAMA, 264(13):1693-1697, 1990

Notable Books

Gibson, Rosemary & Prasad Singh, Janardan (2010) The Treatment Trap. Chicago: Ivan R. Dee.

Carlat, Daniel (2010) Unhinged: The Trouble with Psychiatry – A Doctor’s Revelations about a Profession in Crisis. New York: Free Press.

Petersen, Melody (2009) Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves Into Slick Marketing Machines and Hooked the Nation on Prescription Drugs. New York: Farrar, Straus, and Giroux.

Brody, Howard (2007) Hooked: Ethics, the Medical Profession, and the Pharmaceutical Industry.  New York: Rowman and Littlefield Publishers, Inc.

Petryna, Adriana, Andrew Lakoff, and Arthur Kleinman (2006) Global Pharmaceuticals: Ethics, Markets, Practices. Durham: Duke University Press.

Weber, Leonard (2006) Profits Before People?  Ethical Standards and the Marketing of Prescription Drugs.  Bloomington: Indiana University Press.

Goozner, Merrill (2005) The $800 Million Pill: The Truth Behind the Cost of New Drugs. Berkeley: University of California Press.

Kassirer, Jerome P. (2005) On The Take: How Medicine’s Complicity With Big Business Can Endanger Your Health. New York: Oxford University Press.

Santoro, Michael and Thomas M. Gorrie, eds. (2005) Ethics and the Pharmaceutical Industry.  New York: Cambridge University Press.

Avorn, Jerry (2004) Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs.  New York: Alfred A. Knopf.

Angell, Marcia (2004) The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House.

Silverman, Milton and Philip R. Lee (1974) Pills, Profits, and Politics.  Berkeley: University of California Press.